close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.18 +0.28 (+1.12%)
Official Closing Price Updated: 4:10 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
2 Predictions for Pfizer in 2026 ↗
The company's prospects are stronger than its stock-market performance in 2025 suggests. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge
As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the... 
Via PredictStreet
Topics Economy Intellectual Property Stocks
News headline image
The Great Rebound: US M&A Poised for Record-Breaking 2026 as Interest Rates Stabilize
As the calendar turns to January 1, 2026, the United States financial markets are witnessing a dramatic transformation in the landscape of corporate dealmaking. After a multi-year "deal desert"... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical... 
Via MarketMinute
Topics Intellectual Property
News headline image
Economic Revolution or Looming Recession? Trump’s ‘A++’ Claims Clash with Wall Street’s Cautious 2026 Outlook
As the sun rises on January 1, 2026, the United States finds itself at a historical crossroads, caught between the triumphant rhetoric of an "Economic Revolution" and the sobering data of a cooling... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Should You Buy Pfizer While It's Under $30? ↗
It might not pay off immediately, but it could, eventually. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
News headline image
Investing $122,100 in These 3 High-Yield Dividend Stocks Could Make You $10,000 in Reliable Passive Income in 2026 ↗
The money could flow in with these great dividend stocks. 
Via The Motley Fool
News headline image
1 Momentum Stock to Target This Week and 2 That Underwhelm
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
News headline image
Where Will Pfizer Be in 5 Years? ↗
Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake ↗
Via MarketBeat
News headline image
2 Unstoppable Dividend Stocks to Double Up on Right Now ↗
It's always a great time to buy quality dividend stocks. 
Via The Motley Fool
News headline image
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January. 
Via Stocktwits
Topics Economy Government
News headline image
Tuesday's session: most active stock in the S&P500 index ↗
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Tuesday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
News headline image
The Trillion-Dollar Shuffle: How Year-End Institutional Rebalancing is Fueling Late-December Volatility
As the final trading days of 2025 unfold, the financial markets are witnessing a phenomenon that analysts have dubbed the "Great Rebalancing." While the S&P 500 is poised to finish the year with... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Hunterbrook Capital Bets Big on Achieve Life Sciences: Why a 'Toxic Tree' Could Disrupt the Multi-Billion Dollar Smoking Cessation Market
In a move that has sent ripples through the biotech sector on the final trading days of the year, Hunterbrook Capital announced a significant bullish position in Achieve Life Sciences (NASDAQ:ACHV)... 
Via MarketMinute
Topics Product Recall
News headline image
Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook ↗
The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026. 
Via Stocktwits
News headline image
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? ↗
The stock has been on the rebound for several months, but can it keep the momentum going? 
Via The Motley Fool
Topics Intellectual Property
News headline image
The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year
As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Want $300 in Super-Safe Dividend Income in 2026? Invest $2,670 Into the Following 3 Ultra-High-Yield Stocks. ↗
These high-octane dividend stocks -- sporting an average yield of 11.25% -- have the catalysts needed to sustainably pad the pocketbooks of income seekers. 
Via The Motley Fool
News headline image
Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
News headline image
The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance
As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
The Smartest Dividend Stocks to Buy With $3,000 Right Now ↗
These income stocks look like smart buys right now. 
Via The Motley Fool
News headline image
3 Drug Stocks to Buy at a Discount ↗
The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Superb High-Yield Dividend Stocks With Yields North of 5% That Make for No-Brainer Buys Right Now ↗
High dividend yields don't matter if they aren't supported by quality businesses. 
Via The Motley Fool
News headline image
Looking for the most active stocks in the S&P500 index on Friday? ↗
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Friday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today